TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung and liver failure.
Company profile
Ticker
TMDX
Exchange
Website
CEO
Waleed H. Hassanein
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Medtronic • Varian Medical Systems • Conmed • Integer • Masimo • Natus Medical • LivaNova • GigCapital5 • Outset Medical • Fonar ...
SEC CIK
TMDX stock data
Analyst ratings and price targets
Latest filings (excl ownership)
10-K
2022 FY
Annual report
27 Feb 23
8-K
Departure of Directors or Certain Officers
24 Feb 23
8-K
TransMedics Reports Fourth Quarter and Full Year 2022 Financial Results
22 Feb 23
8-K
Amendments to Articles of Incorporation or Bylaws
4 Nov 22
10-Q
2022 Q3
Quarterly report
4 Nov 22
8-K
TransMedics Reports Third Quarter 2022 Financial Results
3 Nov 22
8-K
Other Events
8 Aug 22
424B5
Prospectus supplement for primary offering
5 Aug 22
424B5
Prospectus supplement for primary offering
3 Aug 22
S-3ASR
Automatic shelf registration
3 Aug 22
Transcripts
TMDX
Earnings call transcript
2022 Q4
22 Feb 23
TMDX
Earnings call transcript
2022 Q3
3 Nov 22
TMDX
Earnings call transcript
2022 Q2
2 Aug 22
TMDX
Earnings call transcript
2022 Q1
4 May 22
TMDX
Earnings call transcript
2021 Q4
24 Feb 22
TMDX
Earnings call transcript
2021 Q3
10 Nov 21
TMDX
Earnings call transcript
2021 Q2
8 Aug 21
TMDX
Earnings call transcript
2021 Q1
5 May 21
TMDX
Earnings call transcript
2020 Q4
3 Mar 21
TMDX
Earnings call transcript
2020 Q3
4 Nov 20
Latest ownership filings
Financial summary
| Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 201.68 mm | 201.68 mm | 201.68 mm | 201.68 mm | 201.68 mm | 201.68 mm |
| Cash burn (monthly) | 1.09 mm | (no burn) | 2.26 mm | 3.02 mm | 1.35 mm | 3.82 mm |
| Cash used (since last report) | 3.22 mm | n/a | 6.65 mm | 8.89 mm | 3.96 mm | 11.24 mm |
| Cash remaining | 198.46 mm | n/a | 195.03 mm | 192.79 mm | 197.72 mm | 190.44 mm |
| Runway (months of cash) | 181.5 | n/a | 86.3 | 63.8 | 147.0 | 49.9 |
Institutional ownership, Q4 2022
86.3% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 198 |
| Opened positions | 37 |
| Closed positions | 15 |
| Increased positions | 76 |
| Reduced positions | 63 |
| 13F shares | Current |
|---|---|
| Total value | 1.70 tn |
| Total shares | 27.77 mm |
| Total puts | 23.50 k |
| Total calls | 260.60 k |
| Total put/call ratio | 0.1 |
| Largest owners | Shares | Value |
|---|---|---|
| FMR | 3.28 mm | $202.24 bn |
| BLK Blackrock | 2.31 mm | $142.62 bn |
| MCQEF Macquarie | 1.95 mm | $120.20 bn |
| Vanguard | 1.69 mm | $104.39 bn |
| Lord, Abbett & Co. | 1.19 mm | $73.25 bn |
| Driehaus Capital Management | 1.10 mm | $67.98 bn |
| Credit Suisse | 1.04 mm | $64.02 bn |
| Summit Partners Public Asset Management | 957.28 k | $59.08 bn |
| STT State Street | 707.39 k | $43.66 bn |
| BLVGF Bellevue | 682.06 k | $42.10 bn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 10 Mar 23 | Waleed H Hassanein | Common Stock | Option exercise | Acquire M | No | No | 2.21 | 193,074 | 426.69 k | 574,191 |
| 10 Mar 23 | Waleed H Hassanein | Stock Option Common Stock | Option exercise | Dispose M | No | No | 2.21 | 193,074 | 426.69 k | 1 |
| 1 Mar 23 | Basile Edward M | Common Stock | Sell | Dispose S | No | No | 80.1 | 3,500 | 280.35 k | 14,314 |
| 1 Mar 23 | Waleed H Hassanein | Common Stock | Sell | Dispose S | No | Yes | 81.01 | 4,900 | 396.95 k | 381,117 |
| 1 Mar 23 | Waleed H Hassanein | Common Stock | Sell | Dispose S | No | Yes | 80.17 | 2,600 | 208.44 k | 386,017 |
| 1 Mar 23 | Stephen Gordon | Common Stock | Sell | Dispose S | No | Yes | 79.51 | 5,000 | 397.55 k | 18,789 |
| 1 Mar 23 | Stephen Gordon | Common Stock | Option exercise | Acquire M | No | Yes | 16.14 | 5,000 | 80.70 k | 23,789 |
| 1 Mar 23 | Stephen Gordon | Stock Option Common Stock | Option exercise | Dispose M | No | Yes | 16.14 | 5,000 | 80.70 k | 15,728 |
| 28 Feb 23 | Tamer I Khayal | Common Stock | Sell | Dispose S | Yes | Yes | 80.06 | 5,000 | 400.30 k | 19,776 |
| 28 Feb 23 | Tamer I Khayal | Common Stock | Sell | Dispose S | No | Yes | 80.15 | 10,000 | 801.50 k | 14,375 |
News
Insiders Selling TransMedics Group And 2 Other Stocks
28 Feb 23
Comfort Systems, Gannett, CommScope And Other Big Stocks Moving Higher On Thursday
23 Feb 23
Cowen & Co. Maintains Outperform on TransMedics Group, Raises Price Target to $75
23 Feb 23
Canaccord Genuity Maintains Buy on TransMedics Group, Raises Price Target to $78
23 Feb 23
JP Morgan Maintains Overweight on TransMedics Group, Raises Price Target to $81
23 Feb 23
Press releases
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
24 Feb 23
TransMedics Reports Fourth Quarter and Full Year 2022 Financial Results
22 Feb 23
TransMedics to Present at Upcoming March Investor Conferences
21 Feb 23
TransMedics to Report Fourth Quarter and Full Year 2022 Financial Results on February 22, 2023
8 Feb 23
TransMedics Appoints Nick Corcoran as Senior Vice President of Supply Chain and Operations
2 Feb 23